Life Sciences

  • March 09, 2026

    Sullivan & Cromwell Advises Agilent On $950M Biocare Buy

    Agilent Technologies Inc. agreed to acquire Biocare Medical, a specialist in clinical and research pathology solutions, in an all-cash transaction valued at $950 million, the company said Monday.

  • March 09, 2026

    JPMorgan Trims But Can't Escape ERISA Drug Costs Suit

    A New York federal judge pared claims Monday against JPMorgan Chase & Co. in a suit from workers who alleged they paid too much for prescription drugs, but opened discovery on allegations that the bank's contract with its pharmacy benefit manager caused transactions prohibited by federal benefits law.

  • March 06, 2026

    Atty Should've Checked Docket, Says Philips CPAP Judge

    An attorney and his client have no one but themselves to blame for the permanent end to a product liability lawsuit over a recalled Philips sleep breathing machine, a Pennsylvania federal judge said on Friday, saying it was on them to monitor the docket.

  • March 06, 2026

    ExThera Exec Hid Patient Deaths To Keep $10M Deal, DOJ Says

    Medical device company ExThera concealed the deaths of two U.S. patients treated with its unapproved blood filtration device at a clinic in Antigua, according to federal prosecutors, with the company agreeing to forfeit nearly $5.7 million and one executive facing up to three years in prison.

  • March 06, 2026

    FDA Vaccine Chief Prasad To Exit Agency For 2nd Time

    Dr. Vinay Prasad, the U.S. Food and Drug Administration's top vaccine regulator, will leave the agency in the coming weeks, FDA Commissioner Marty Makary said Friday.

  • March 06, 2026

    Drugmaker Nektar Faces Suit Over Hair Loss Drug Trial Claims

    Pharmaceutical company Nektar Therapeutics on Friday was hit with a proposed class action accusing it of harming investors by failing to disclose the risks associated with its failure to follow protocol for enrolling participants in an unsuccessful trial for its hair loss treatment.

  • March 06, 2026

    Actelion Pays $65M To Settle Tracleer Antitrust Class Suit

    Actelion Pharmaceuticals Ltd. agreed to pay $65 million to resolve antitrust claims from a certified class accusing it of illegally denying generics companies the samples they need to produce generic versions of its hypertension drug Tracleer, according to a brief in Maryland federal court seeking preliminary approval of the settlement.

  • March 06, 2026

    9th Circ. Mulls Whether Politics Tainted DOJ Trans Care Probe

    A Ninth Circuit panel on Friday grappled with where to draw the line between a legitimate law enforcement investigation and a politically motivated crusade, as the U.S. Department of Justice sought to revive a subpoena against a telehealth provider of gender-affirming medical care.

  • March 06, 2026

    Boston Scientific Investor Sues Over Growth Projections

    A Boston Scientific Corp. investor has filed a proposed class action against the medical device manufacturer and its top brass, claiming they misled shareholders about the sustainability and growth trajectory of the company's electrophysiology segment while failing to disclose competitive pressures and regulatory headwinds.

  • March 06, 2026

    Mass. Judge Told Vax Committee Must Be Fairly Balanced

    A key federal vaccine committee remains subject to statutory requirements that its membership be fairly balanced, a Massachusetts federal judge heard from both U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. and medical organizations challenging his overhaul of the group.

  • March 06, 2026

    Fed. Circ. Won't Reinstate $2M Sepsis-Testing Patent Verdict

    The Federal Circuit on Friday refused to revive the $2 million jury verdict Magnolia Medical Technologies Inc. won in its sepsis-testing patent infringement suit against Kurin Inc., affirming a Delaware federal judge's decision to throw out the verdict after trial.

  • March 06, 2026

    NJ Talc Suit Will Proceed Amid Beasley Allen DQ Appeal

    The New Jersey Supreme Court has declined to stay multicounty litigation over Johnson & Johnson's talc-based baby powder brought by hundreds of women who allege their ovarian cancer was linked to the product, while Beasley Allen appeals its removal as plaintiff's counsel over a firm partner's collaboration with the pharmaceutical giant's former outside counsel.

  • March 06, 2026

    Sanofi Selling Medley Unit To Brazilian Drug Co. For $500M

    French drugmaker Sanofi will sell 100% of Medley, one of Brazil's leading generic drug brands, to Brazilian pharmaceutical conglomerate Grupo EMS, the companies announced Friday. 

  • March 06, 2026

    Express Scripts Ducks RICO Suit Over Acthar Price Hike

    Express Scripts Inc. and its affiliates may have worked with drugmaker Mallinckrodt to hike the price of seizure medication Acthar from $40 to $40,000, but a proposed class action by third-party payors failed to allege the high prices were a result of fraud, a Pennsylvania federal judge ruled.

  • March 06, 2026

    Pa. High Court Snapshot: AG Powers, Gun Parts, CEO Bonus

    The Pennsylvania Supreme Court this month will revisit a ruling on the state attorney general's power over civil suits brought by county-level district attorneys in a case stemming from the Philadelphia and Pittsburgh district attorneys' objections to a $26 billion opioid settlement.

  • March 06, 2026

    Baker McKenzie Guides Servier On $2.5B Oncology Deal

    French pharmaceutical group Servier said Friday that it has agreed to acquire Day One for about $2.5 billion in cash, with legal guidance from Baker McKenzie.

  • March 05, 2026

    Telehealth Co. Swaps In Gordon Rees In Novo's GLP-1 Fight

    A telehealth platform facing allegations from Novo Nordisk that it falsely advertised Ozempic alternatives has picked new counsel in the dispute, withdrawing attorneys from Foley & Lardner LLP and Miller Nash LLP and substituting in two lawyers from Gordon Rees Scully Mansukhani LLP.

  • March 05, 2026

    Fintech Sues Deutsche Bank, Pathward Over Pharma Flags

    A self-described barter-based payment platform sued Deutsche Bank AG and Pathward NA, alleging it was improperly placed on an industry blacklist following the banks' assertions it was "transaction laundering" for companies selling gray-market peptides.

  • March 05, 2026

    Top Patent Officials To Review Sanofi's Double Patenting Win

    U.S. Patent and Trademark Office Director John Squires on Thursday announced he'll be reviewing whether the Patent Trial and Appeal Board properly approved Sanofi's patent application after an obviousness-type double patenting rejection.

  • March 05, 2026

    Pharma Co. Investors Secure Class Cert. Over FDA Obstacles

    A Pennsylvania federal judge has granted certification to a group of Verrica Pharmaceuticals Inc. investors who claim the company defrauded them by hiding obstacles it faced in obtaining approval from the U.S. Food and Drug Administration for its lead product, though she made a slight change to the class definition to avoid what she called a "heads I win, tails you lose strategy."

  • March 05, 2026

    Drugmaker Aquestive Hit With Suit Over FDA Approval Delay

    Pharmaceutical company Aquestive Therapeutics Inc. has been hit with a proposed class action accusing it of harming investors by failing to disclose the likelihood that the U.S. Food and Drug Administration would delay approval of the company's drug application for its allergic reaction treatment.

  • March 05, 2026

    Pfizer Gets OK For $29M SEC Payout From Insider Case

    A New York federal judge on Thursday approved a request from the U.S. Securities and Exchange Commission and Pfizer to have $29 million paid out to a Pfizer subsidiary from the roughly $75.2 million distribution left over from a $602 million insider trading deal.

  • March 05, 2026

    Progenity Investors' $1M Billing Fraud Suit Deal Gets Final OK

    Genetic test distributor Progenity Inc., now known as Biora Therapeutics Inc., has received final approval of a $1 million settlement with investors, resolving claims that it made misleading statements ahead of its June 2020 initial public offering about its practice of overbilling the government.

  • March 05, 2026

    Fed. Circ. Mulls Patents In Penile Implant Trade Secret Win

    A Federal Circuit panel on Thursday grilled both sides in a trade secret dispute over penile implants that resulted in an $18.3 million judgment against defendants, repeatedly questioning attorneys about whether existing patents doomed the trade secrets claimed by International Medical Devices and its founder, Dr. James Elist.

  • March 05, 2026

    9th Circ. Judge 'Frustrated' At DOJ Position On Anti-Trans EOs

    A Ninth Circuit judge said Thursday he's "very frustrated" with the Trump administration's argument that a district court judge acted prematurely by partly blocking executive orders to end funding for gender-affirming care, saying it's "pretty clear" the government was poised to do exactly that.

Expert Analysis

  • Series

    Playing Tennis Makes Me A Better Lawyer

    Author Photo

    An instinct to turn pain into purpose meant frequent trips to the tennis court, where learning to move ahead one point at a time was a lesson that also applied to the steep learning curve of patent prosecution law, says Daniel Henry at Marshall Gerstein.

  • Expect Major Shifts In Patent And Trademark Policy This Year

    Author Photo

    New leadership and initiatives promise to bring consequential changes to the U.S. Patent and Trademark Office's practices in 2026, likely favoring patent allowance and issuance, as well as streamlining trademark processes, say attorneys at Knobbe Martens.

  • Class Actions At The Circuit Courts: January Lessons

    Author Photo

    In this month's review of class action appeals, Mitchell Engel at Shook Hardy discusses five rulings from October and November, and identifies practice tips from cases involving consumer fraud, oil and gas leases, toxic torts, and wage and hour issues.

  • Series

    Judges On AI: How Judicial Use Informs Guardrails

    Author Photo

    U.S. Magistrate Judge Maritza Dominguez Braswell at the U.S. District Court for the District of Colorado discusses why having a sense of how generative AI tools behave, where they add value, where they introduce risk and how they are reshaping the practice of law is key for today's judges.

  • What US Cos. Must Know To Comply With Italy's AI Law

    Author Photo

    Italy's newly effective artificial intelligence law means U.S. companies operating in Italy or serving Italian customers must now meet EU AI Act obligations as well as Italy-specific requirements, including immediately enforceable criminal penalties, designated national authorities and sector-specific mandates, say attorneys at Portolano Cavallo.

  • Ag Bill Wording Presents Existential Threat To Hemp Industry

    Author Photo

    A proposal in the agriculture appropriations bill for fiscal year 2026, which excludes almost everything synthesized from cannabis from the legal definition of “hemp,” would have catastrophic consequences for thousands of farmers, medical researchers and businesses by banning everything from intoxicating delta-9 THC products to topical CBD creams, says Alissa "Ali" Jubelirer at Benesch.

  • Series

    Adapting To Private Practice: 5 Tips From Ex-SEC Unit Chief

    Author Photo

    My move to private practice has reaffirmed my belief in the value of adaptability, collaboration and strategic thinking — qualities that are essential not only for successful client outcomes, but also for sustained professional satisfaction, says Dabney O’Riordan at Fried Frank.

  • 5 Drug Pricing Policy Developments To Watch In 2026

    Author Photo

    2026 may prove to be a critical year for drug pricing in the U.S., with potential major shifts including several legislative initiatives moving forward after being in the works for years, and more experimentation on the horizon concerning GLP-1s and Section 340B pricing, say attorneys at Manatt.

  • Patent Applicants Must Get Biologics Enablement Right

    Author Photo

    As artificial intelligence increasingly becomes a core driver in drug discovery, it is critical for drug companies to adapt their drafting strategies to the unique features of AI-generated inventions, and to pay particularly close attention to enablement standards, says Sanandan Malhotra at Novo Nordisk.

  • Series

    Law School's Missed Lessons: How To Start A Law Firm

    Author Photo

    Launching and sustaining a law firm requires skills most law schools don't teach, but every lawyer should understand a few core principles that can make the leap calculated rather than reckless, says Sam Katz at Athlaw.

  • Fed. Circ. Patent Decisions In 2025: An Empirical Review

    Author Photo

    In 2025, the Federal Circuit's increased output was not enough to keep up with its ever-growing patent case load, and patent owners and applicants fared poorly overall as the court's affirmance rate fell, says Dan Bagatell at Perkins Coie.

  • Regulatory Uncertainty Ahead For Organ Transplant System

    Author Photo

    Pending court cases against a Centers for Medicare and Medicaid Services final rule that introduced a competition-centric model for assessing organ procurement organizations' performance will significantly influence the path forward for such organizations and transplant hospitals, say attorneys at Crowell & Moring.

  • Key False Claims Act Trends From The Last Year

    Author Photo

    The False Claims Act remains a powerful enforcement tool after some record verdicts and settlements in 2025, and while traditional fraud areas remain a priority, new initiatives are raising questions about its expanding application, says Veronica Nannis at Joseph Greenwald.

  • Opinion

    It's Too Soon To Remove Suicide Warnings From GLP-1 Drugs

    Author Photo

    The U.S. Food and Drug Administration's decision this month to order removal of warnings about the risk of suicidal thoughts from GLP-1 weight-loss drugs is premature — and from a safety and legal standpoint, the downside of acting too soon could be profound, says Sean Domnick at Rafferty Domnick.

  • Series

    Hosting Exchange Students Makes Me A Better Lawyer

    Author Photo

    Opening my home to foreign exchange students makes me a better lawyer not just because prioritizing visiting high schoolers forces me to hone my organization and time management skills but also because sharing the study-abroad experience with newcomers and locals reconnects me to my community, says Alison Lippa at Nicolaides Fink.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.